Image Place holder

Hien Duong Liu, MD


Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Hodgkin Lymphoma , Non-Hodgkin Lymphoma

Dr. Hien Liu is Medical Director of the Apheresis Unit and an Associate Member in the Moffitt Cancer Center Department of Blood and Marrow Transplant and Cellular Immunotherapy. Dr. Liu earned her MD from the University of Michigan Medical School. She completed an Internal Medicine Residency at Michigan State University/Grand Rapids Medical Education and Research Center. Dr. Liu completed a Hematology/Oncology Fellowship at Cleveland Clinic Foundation, where she also served as Chief Fellow. Prior to joining Moffitt, Dr. Liu was an Assistant Professor at Cleveland Clinic Lerner College of Medicine and Associate Member at Case Comprehensive Cancer Center, Cleveland, Ohio. Dr. Liu is an experienced blood and marrow transplant physician, specializing in autologous and allogeneic transplant for lymphoid malignancies, as well as chimeric antigen receptor (CAR) T-cell therapy. Her clinical and research interests include peripheral blood stem cell mobilization strategies, leukapheresis for CAR T, and therapeutic photopheresis. Dr. Liu leads the Moffitt Apheresis Unit, where peripheral blood stem cell collections for hematopoietic stem cell transplant donors and cellular therapy patients are performed. In addition, she is part of the team of lymphoma physicians that see and perform CAR T-cell therapy for lymphoid cancers.

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine
  • Hematology
  • Internal Medicine

Fellowship:

  • Cleveland Clinic Foundation - Hematology/Oncology

Residency:

  • Michigan State University/Grand Rapids Medical Education and Research Center - Internal Medicine

Medical School:

  • University of Michigan Medical School - MD
Participating Trials

CLINICAL TRIAL 19627
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Condition: Malignant Hematology
Intervention: Rituxan (rituximab); Rituxan Hycela; rituximab
Open

CLINICAL TRIAL 19341
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Condition: Immunotherapy
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; MESNA; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19800
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Condition: Malignant Hematology
Intervention: KD025
Open

CLINICAL TRIAL 19721
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19962
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+Subjects with Relapsed/Refractory HPV16+ Cancers
Condition: Head & Neck
Intervention: KITE-439; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19961
A Phase 1B/2 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Eq001 In Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Condition: Malignant Hematology
Intervention: EQ001; Placebo
Open

CLINICAL TRIAL 19960
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-Cd19 Allogeneic Car T Cell Therapy in Patients with Relapsed/Refractory Large B-Cell and Follicular Lymphoma
Condition: Malignant Hematology
Intervention: ALLO-501; ALLO-647; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19877
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab; Varlilumab
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplant. Bone Marrow Transplant. 2019 May. Pubmedid: 31092900.
  • Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Tr. 2019 Mar;25(3):e76-e85. Pubmedid: 30576834.
  • Sim AJ, Jain MD, Figura N, Chavez JC, Shah BD, Khimani F, Lazarayan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim SU, Locke FL, Robinson TJ. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2019 Jun. Pubmedid: 31175906.
  • Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Stanghellini MTL, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers ME, Shaw BE, Petriček I. Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working. Biol Blood Marrow Tr. 2019 Feb;25(2):e46-e54. Pubmedid: 30481594. Pmcid: PMC6362842.
  • Khouri J, Kin A, Thapa B, Reu FJ, Bumma N, Samaras CJ, Liu HD, Karam MA, Reed J, Mathur S, Faiman BM, Devries G, Zonder J, Valent J. Daratumumab proves safe and highly effective in AL amyloidosis. Brit J Haematol. 2019 Apr;185(2):342-344. Pubmedid: 29938774.
  • Chakraborty R, Liu HD, Rybicki L, Tomer J, Khouri J, Dean RM, Faiman BM, Kalaycio M, Samaras CJ, Majhail NS, Valent J. Progression with clinical features is associated with worse subsequent survival in multiple myeloma. Am J Hematol. 2019 Apr;94(4):439-445. Pubmedid: 30663805.
  • Arora S, Majhail NS, Liu H. Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era. Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):200-205. Pubmedid: 30679106.
  • Khouri J, Reu F, Majhail NS, Gerds A, Jagadeesh D, Dean R, Sobecks R, Hamilton BK, Pohlman B, Hill BT, Corrigan D, Kalaycio M, Bolwell BJ, Liu HD. Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Apr. Pubmedid: 31053548.
  • Patel SS, Rybicki LA, Corrigan D, Dumont C, Bolwell B, Dean R, Figueroa P, Hanna R, Liu H, Gerds AT, Hill B, Jagadeesh D, Kalaycio M, Pohlman B, Ricci K, Sobecks R, Lu W, Hamilton BK, Majhail NS. Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2018 Oct;54(5):775-781. Pubmedid: 30375493.
  • Patel SS, Rybicki LA, Corrigan D, Bolwell B, Dean R, Liu H, Gerds AT, Hanna R, Hill B, Jagadeesh D, Kalaycio M, Pohlman B, Sobecks R, Majhail NS, Hamilton BK. Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2018 May;24(5):1029-1034. Pubmedid: 29369800. Pmcid: PMC5953837.
  • Winter A, Rybicki L, Shah SN, Jagadeesh D, Gerds AT, Hamilton BK, Liu H, Dean R, Sobecks R, Pohlman B, Smith M, Kalaycio M, Bolwell BJ, Majhail NS, Hill BT. Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma. 2018 May;59(5):1195-1201. Pubmedid: 28853617.
  • Khouri J, Rybicki L, Majhail N, Kalaycio M, Copelan E, Pohlman B, Hill B, Dean R, Lazaryan A, Hamilton B, Andresen S, Sobecks R, Bolwell B, Liu H. Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days. J Clin Apher. 2018 Jun;33(3):303-309. Pubmedid: 29134688.
  • Sawalha Y, Hill BT, Rybicki LA, Sun D, Dean RM, Jagadeesh D, Hamilton BK, Gerds AT, Sobecks RM, Andresen S, Liu HK, Majhail NS, Pohlman B, Kalaycio ME, Bolwell BJ, Smith MR. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e95-e102. Pubmedid: 29208403.
  • Mustafa Ali M, Corrigan DM, Rybicki LA, Yurch MA, Cherni K, Liu H, Dean R, Hamilton B, Pohlman B, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS, Sobecks R. Intravenous compared to oral busulfan with cyclophosphamide for autologous hematopoietic cell transplant conditioning for plasma cell myeloma. Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):253-256. Pubmedid: 29705567.
  • Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini MT, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Petriček I. Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2018 Dec;54(5):662-673. Pubmedid: 30531954.
  • Bates D, Bolwell B, Majhail NS, Rybicki L, Yurch M, Abounader D, Kohuth J, Jarancik S, Koniarczyk H, McLellan L, Dabney J, Lawrence C, Gallagher L, Kalaycio M, Sobecks R, Dean R, Hill B, Pohlman B, Hamilton BK, Gerds AT, Jagadeesh D, Liu HD. Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study. Biol Blood Marrow Tr. 2017 Sep;23(9):1567-1572. Pubmedid: 28533058.
  • Mustafa Ali M, Abounader DM, Rybicki LA, Yurch MA, Starn J, Ferraro C, Winslow V, Hamilton BK, Gerds AT, Liu H, Dean R, Hill BT, Pohlman B, Andresen S, Hanna R, Kalaycio M, Bolwell BJ, Majhail NS, Sobecks RM. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biol Blood Marrow Tr. 2017 May;23(5):776-781. Pubmedid: 28108271.
  • Gokhale A, Quraishy N, Veemara V, Howdyshell H, Murray L, Royer J, Salmi L, Ricci K, Liu H. Clotting during autologous hematopoietic progenitor cells collection. J Clin Apher. 2017 Dec;32(6):560-561. Pubmedid: 28485035.
  • Gokhale A, Quraishy N, Royer J, Howdyshell H, Murray L, Salmi L, Veemara V, Ricci K, Liu H. Centrifuge bowl leak during extracorporeal photopheresis. Transfusion. 2017 Aug;57(8):1860-1861. Pubmedid: 28782819.
  • Hill BT, Rybicki L, Carlstrom KD, Jagadeesh D, Gerds A, Hamilton B, Liu H, Dean R, Sobecks R, Pohlman B, Andresen S, Kalaycio M, Bolwell BJ, Majhail NS. Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biol Blood Marrow Tr. 2016 Sep;22(9):1588-1595. Pubmedid: 27343718.
  • Hong S, Rybicki L, Abounader DM, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS. Association of socioeconomic status with autologous hematopoietic cell transplantation outcomes for lymphoma. Bone Marrow Transplant. 2016 Sep;51(9):1191-1196. Pubmedid: 27111046.
  • Liu HD. The Cost of Mobilization. Biol Blood Marrow Tr. 2016 Oct;22(10):1735-1736. Pubmedid: 27538375.
  • Holtan SG, Khera N, Levine JE, Chai X, Storer B, Liu HD, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Flowers ME, Cutler CS, Lukez A, Arai S, Lazaryan A, Newell LF, Krupski C, Jagasia MH, Pusic I, Wood W, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Watanaboonyongcharoen P, Efebera YA, Ferrara JL, Panoskaltsis-Mortari A, Weisdorf D, Lee SJ, Pidala J. Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. Blood. 2016 Nov;128(19):2350-2358. Pubmedid: 27625357. Pmcid: PMC5106113.
  • Hong S, Rybicki L, Abounader D, Bolwell BJ, Dean R, Gerds AT, Hamilton BK, Hill BT, Jagadeesh D, Kalaycio M, Liu HD, Pohlman B, Sobecks R, Majhail NS. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Tr. 2016 Jun;22(6):1141-1144. Pubmedid: 26995694.
  • Hong S, Valent J, Rybicki L, Abounader D, Bolwell B, Dean R, Gerds AT, Jagadeesh D, Hamilton BK, Hill B, Kalaycio ME, Pohlman B, Reu F, Samaras C, Sobecks R, Majhail NS, Liu HD. Outcomes of autologous hematopoietic cell transplantation in primary amyloidosis after bortezomib-based induction therapy. Bone Marrow Transplant. 2016 05;51(5):732-734. Pubmedid: 26726941.
  • Fu S, Rybicki L, Abounader D, Andresen S, Bolwell BJ, Dean R, Gerds A, Hamilton BK, Hanna R, Hill BT, Jagadeesh D, Kalaycio ME, Liu HD, Pohlman B, Sobecks RM, Majhail NS. Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Oct;50(10):1326-1330. Pubmedid: 26191953.